Connect Biopharma is trading 5.3% down at $1.25 after its Phase 2 Seabreeze STAT asthma trial missed statistical significance.
- The primary Day 28 treatment-failure endpoint missed significance despite a 66% reduction versus placebo.
- Lung-function improvement at Day 7 was statistically significant.
- The September 22 decline follows continued reassessment of the results, while broader markets were modestly higher.